Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

should be classified as a reduction of equity and, accordingly, did not record any reserve charges during the first quarter of 2009. These decreases were partially offset by a $0.1 million increase in professional fees associated with the preparation of the Company's SEC filings.

The Company recorded net interest and other expense of $1.2 million for the first quarter of 2009 compared to net interest and other income of $0.1 million for the first quarter of 2008. The decrease in net interest and other income resulted from an additional impairment in the amount of $0.9 million to the Company's auction rate securities due primarily to their continued illiquidity and a $0.4 million decrease in interest income, due to a decrease in cash and short-term investments during the quarter.

As a result, the Company's net loss for the quarter ended March 31, 2009 was $8.3 million compared to a net loss of $7.8 million for the quarter ended March 31, 2009. The loss for the quarter ended March 31, 2008 includes a loss from discontinued operations of $0.7 million.

As of March 31, 2009, the Company had $25.6 million in cash and investments (including auction rate securities recorded at their fair value) compared to $33.9 million as of December 31, 2008. The decrease of $8.3 million was due to cash spent during the first quarter of $7.4 million and an impairment to the auction rate securities of $0.9 million discussed above. Cash and short-term investments as of March 31, 2009 are net of $2.1 million in cumulative impairment charges recorded for the company's auction rate securities. Based on the amount of cash and short-term investments on hand, the $11.0 million received from the sale of common stock to Cadila on April 1, 2009, the approximately $7.5 million received from sales of common stock under the Wm Smith & Co. sales agreement through May 5, 2009, along with the Company's intention to pay 50% of the balance of its
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 Alton Housing Authority was hit ... 2013 said that their presence has already caused the ... sufferers avoid such big spending, My Cleaning Products shared a ... It was said in the report that to clear the ... Apart from that, its employees also attended a mandatory training ...
(Date:5/22/2013)...  Moderna Therapeutics, the pioneering company developing messenger RNA ... in vivo production of therapeutic proteins, announced ... join Moderna in early July as its first Chief ... leader in the design and implementation of information systems ... translation, clinical operations and commercial preparedness. John has also ...
(Date:5/21/2013)... Belmont, MA (PRWEB) May 21, 2013 ... complete tracking to reporting eLearning solution using Tin ... report and dashboard tool. CLD is a leading ... biotech, and medical device companies worldwide. , ... tracking standard that helps learners and trainers more ...
(Date:5/21/2013)... 2013 The congress of the ... is the biggest congress in Europe ... participants are in Istanbul to ... New pioneering studies have been presented: / ... ADMINISTERED VIA HEMODIALYSATE REDUCES ESA USE" By ...
Breaking Biology Technology:Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3
... NEWTOWN, Pa., Oct. 19 Quotient Biodiagnostics, Inc., today ... has approved its biologics license application (BLA) for the ... transfusion diagnostics. These products are for use by ... and screen blood. , Quotient Biodiagnostics was formed ...
... -- Fate Therapeutics, Inc. ... cells (iPSCs) using a combination of small molecules that ... The discoveries, which were made by Sheng Ding, Ph.D., ... Scripps Research Institute (TSRI), represent a more than 200 ...
... Ga., Oct. 16 Cellu Tissue Holdings, Inc. ("Cellu ... Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") ... common stock. The offered shares will include shares to be ... of the company. The total number of shares to be ...
Cached Biology Technology:Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance To Enter U.S. Transfusion Diagnostics Market 2Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 2Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 3Cellu Tissue Holdings, Inc. Files Registration Statement for Proposed Initial Public Offering of Common Stock 2
(Date:5/21/2013)... ARBORThe new University of Michigan Water Center today ... support Great Lakes restoration and protection efforts. , ... support diverse projects, including efforts to track the ... of techniques to control non-native weedy plant invasions; ... monitor fish responses to restoration activities. , The ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Fueling fitness on the final frontier 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... name, indicates a disease of the respiratory tract. But ... nervous system problems, according to an article in the ... online. , SARS, a potentially fatal illness caused by ... of 2003. The disease is usually transmitted by contact ...
... study has found that maturing stands of pines exposed ... mid-century produce more needles than those absorbing today's levels ... study also found that lack of soil nutrients may ... Heather McCarthy will describe results she obtained from a ...
... common childhood cancer is cured in about 80 percent ... closer to five percent. In efforts to further increase ... Hospital, the University of Tennessee, and the University of ... role in the effectiveness of chemotherapy drugs. Their findings ...
Cached Biology News:New study shows SARS can infect brain tissue 2High carbon dioxide levels spur Southern pines to grow more needles 2High carbon dioxide levels spur Southern pines to grow more needles 3Genes linked to treatment resistance in children with leukemia 2
... Factor XIII in both reduced and non-reduced ... XIII B-chain or human Factor XII. Factor XIII ... composed of two subunits. Factor XIII-A is the ... 160kDa. Factor XIII is present in plasma as ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: